Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

  • Technology appraisal guidance
  • TA816
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence